Intestinal disease secondary to tocilizumab

Rev Esp Enferm Dig. 2022 Dec;114(12):755-756. doi: 10.17235/reed.2022.8818/2022.

Abstract

It is presented a case study of intestinal affectation on a patient under tocilizumab treatment for giant cell arteritis.

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Drug Therapy, Combination
  • Giant Cell Arteritis* / drug therapy
  • Humans
  • Intestinal Diseases*

Substances

  • tocilizumab
  • Antibodies, Monoclonal, Humanized